Bear,,,,,agreed,,,,,but it is hard to argue the point that the RVX team have no reasonable concept about the placebo arm numbers anticipated in the trial extension. It must be assumed that the event numbers on that side are within limits from many years of world wide research data which our MACE numbers in this trial would have been based on.

Even when they extended the trial, target numbers have been given out by RVX. The most influential wild card in the mix and of course not the only one would be the decline of events on the 208 side, if any. Thats what I see in this circus of missed timings, missed deals and delayed PPs. The newly announced additional PPs are most likely awaiting news of completion or other indications we are not privy to!. its just an opinion.